ASH News Daily 2013 - Day 3 - (Page B-33)
NOW AVAILABLE
To learn more about MARQIBO, please visit the Spectrum booth (3409).
Indication
MARQIBO is indicated for the treatment of adult patients with Philadelphia
chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater
relapse or whose disease has progressed following 2 or more anti-leukemia therapies.
This indication is based on overall response rate. Clinical benefit such as improvement
in overall survival has not been verified.
IMPORTANT SAFETY INFORMATION
WARNING
* For Intravenous Use Only-Fatal if Given by Other Routes
* Death has occurred with intrathecal administration
* MARQIBO has different dosage recommendations than vincristine
sulfate injection. Verify drug name and dose prior to preparation and
administration to avoid overdosage
Contraindications
* MARQIBO is contraindicated in patients with demyelinating conditions, including
Charcot-Marie-Tooth syndrome; in patients with hypersensitivity to vincristine sulfate
or any of the other components of MARQIBO; and for intrathecal administration
Warnings and Precautions
* MARQIBO is for intravenous use only-fatal if given by other routes. Intrathecal use
is fatal. Extravasation causes tissue injury. If extravasation is suspected, discontinue
infusion immediately and consider local treatment measures
* Sensory and motor neuropathy are common and cumulative. Monitor patients
for peripheral motor and sensory, central and autonomic neuropathy and reduce,
interrupt, or discontinue dosing. Patients with preexisting severe neuropathy should
be treated with MARQIBO only after careful risk-benefit assessment
* Neutropenia, thrombocytopenia, or anemia may occur. Monitor blood counts prior
to each dose. Consider dose modification or reduction as well as supportive care
measures if Grade 3 or 4 myelosuppression develops
* Anticipate, monitor for, and manage tumor lysis syndrome
* A prophylactic bowel regimen should be instituted with MARQIBO to prevent
constipation, bowel obstruction, and/or paralytic ileus
* Severe fatigue can occur requiring dose delay, reduction, or discontinuation
of MARQIBO
* Fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred.
Monitor liver function and modify or interrupt dosing for hepatic toxicity
* MARQIBO can cause fetal harm. Advise women of potential risk to fetus
Adverse Events
* The most commonly reported adverse reactions (incidence >30%) in clinical
studies include constipation (57%), nausea (52%), pyrexia (43%), fatigue (41%),
peripheral neuropathy (39%), febrile neutropenia (38%), diarrhea (37%), anemia
(34%), decreased appetite (33%), and insomnia (32%)
* A total of 75.9% of patients experienced serious adverse events (SAEs) during
the studies. The most commonly reported SAEs included febrile neutropenia (20.5%),
pyrexia (13.3%), hypotension (7.2%), respiratory distress (6.0%), and cardiac
arrest (6.0%)
* Twenty-eight percent of patients experienced adverse reactions leading to treatment
discontinuation. The most common adverse reactions that caused treatment
discontinuation were peripheral neuropathy (10%), leukemia-related (7%), and
tumor lysis syndrome (2%)
* Deaths occurred in 23% of patients in study 1. The nonleukemia-related causes
of death were brain infarct (1), intracerebral hemorrhage (2), liver failure (1),
multisystem organ failure (2), pneumonia and septic shock (3), respiratory failure
(4), pulmonary hemorrhage (1), and sudden cardiac death (1)
Drug Interactions
* MARQIBO is expected to interact with drugs known to interact with non-liposomal
vincristine sulfate, therefore the concomitant use of strong CYP3A inhibitors or the
use of potent P-glycoprotein inhibitors or inducers should be avoided
Use in Specific Populations
* The safety and effectiveness of MARQIBO in pediatric patients have not
been established
* It is not known whether MARQIBO is excreted in human milk
Please see Brief Summary of Prescribing Information, including BOXED WARNINGS,
on adjacent pages. Please see Prescribing Information at MARQIBO.com.
©2013 Talon Therapeutics, Inc. MARQIBO is a registered trademark of Talon Therapeutics, Inc.
All rights reserved. October 2013. Printed in the USA. 0111-079800
www.sppirx.com
5947_Marqibo_tabloid_ASH_M.indd 1
10/22/13 4:41 PM
Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 3
Table of Contents
ASH News Daily 2013 - Day 3
https://www.nxtbookmedia.com